These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 35051747)

  • 1. Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.
    Cheng B; Pan W; Xing Y; Xiao Y; Chen J; Xu Z
    Eur J Med Chem; 2022 Feb; 230():114109. PubMed ID: 35051747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The DNA Damaging Revolution: PARP Inhibitors and Beyond.
    Yap TA; Plummer R; Azad NS; Helleday T
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():185-195. PubMed ID: 31099635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolving DNA repair synthetic lethality targets in cancer.
    Kulkarni S; Brownlie J; Jeyapalan JN; Mongan NP; Rakha EA; Madhusudan S
    Biosci Rep; 2022 Dec; 42(12):. PubMed ID: 36420962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer.
    Hu Y; Guo M
    Cancer Sci; 2020 Sep; 111(9):3111-3121. PubMed ID: 32639661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma.
    Das S; Cardin D
    Curr Treat Options Oncol; 2020 Jun; 21(8):62. PubMed ID: 32601814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.
    Gourley C; Balmaña J; Ledermann JA; Serra V; Dent R; Loibl S; Pujade-Lauraine E; Boulton SJ
    J Clin Oncol; 2019 Sep; 37(25):2257-2269. PubMed ID: 31050911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences.
    Carrassa L; Colombo I; Damia G; Bertoni F
    Cancer Treat Rev; 2020 Nov; 90():102090. PubMed ID: 32892059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advancing cancer therapy: new frontiers in targeting DNA damage response.
    Qian J; Liao G; Chen M; Peng RW; Yan X; Du J; Huang R; Pan M; Lin Y; Gong X; Xu G; Zheng B; Chen C; Yang Z
    Front Pharmacol; 2024; 15():1474337. PubMed ID: 39372203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
    Brown JS; O'Carrigan B; Jackson SP; Yap TA
    Cancer Discov; 2017 Jan; 7(1):20-37. PubMed ID: 28003236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA damage response pathways in tumor suppression and cancer treatment.
    Liang Y; Lin SY; Brunicardi FC; Goss J; Li K
    World J Surg; 2009 Apr; 33(4):661-6. PubMed ID: 19034564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment.
    Li S; Wang L; Wang Y; Zhang C; Hong Z; Han Z
    J Hematol Oncol; 2022 Oct; 15(1):147. PubMed ID: 36253861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Directing the use of DDR kinase inhibitors in cancer treatment.
    Brandsma I; Fleuren EDG; Williamson CT; Lord CJ
    Expert Opin Investig Drugs; 2017 Dec; 26(12):1341-1355. PubMed ID: 28984489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Targeting of DNA Damage Response in Cancer.
    Choi W; Lee ES
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations.
    Ngoi NYL; Westin SN; Yap TA
    Curr Opin Oncol; 2022 Sep; 34(5):559-569. PubMed ID: 35787597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA Damage Repair Inhibitor for Breast Cancer Treatment.
    Min A; Lee KH; Im SA
    Adv Exp Med Biol; 2021; 1187():159-179. PubMed ID: 33983578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
    Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on small molecule compounds targeting synthetic lethality for cancer therapy.
    Luo J; Li Y; Zhang Y; Wu D; Ren Y; Liu J; Wang C; Zhang J
    Eur J Med Chem; 2024 Nov; 278():116804. PubMed ID: 39241482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment.
    Maresca L; Stecca B; Carrassa L
    Cells; 2022 Apr; 11(9):. PubMed ID: 35563772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the DNA damage response for cancer therapy.
    Curtin NJ
    Biochem Soc Trans; 2023 Feb; 51(1):207-221. PubMed ID: 36606678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
    Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
    Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.